Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hypera SA (HYPMY)
OTHER OTC:HYPMY
Holding HYPMY?
Track your performance easily
HYPMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.75 - $7.46
Previous Close$2.97
Volume51.17K
Average Volume (3M)20.08K
Market Cap
$1.88B
Enterprise Value$3.00B
Total Cash (Recent Filing)R$2.86B
Total Debt (Recent Filing)R$9.68B
Price to Earnings (P/E)6.2
Beta0.63
Next Earnings
Feb 20, 2025EPS EstimateN/A
Last Dividend Ex-Date
Oct 04, 2024Dividend Yield4.32%
Share Statistics
EPS (TTM)0.48
Shares OutstandingN/A
10 Day Avg. Volume19,028
30 Day Avg. Volume20,078
Standard Deviation0.12
R-Squared0.19
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)3.03
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Hypera SA News
PremiumCompany Announcements
Hypera S.A. Reports Strategic Shift Amid Revenue Decline
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
HYPMY FAQ
What was Hypera SA’s price range in the past 12 months?
Hypera SA lowest stock price was $2.75 and its highest was $7.46 in the past 12 months.
What is Hypera SA’s market cap?
Currently, no data Available
When is Hypera SA’s upcoming earnings report date?
Hypera SA’s upcoming earnings report date is Feb 20, 2025 which is in 58 days.
How were Hypera SA’s earnings last quarter?
Hypera SA released its earnings results on Nov 13, 2024. The company reported $0.107 earnings per share for the quarter, beating the consensus estimate of N/A by $0.107.
Is Hypera SA overvalued?
According to Wall Street analysts Hypera SA’s price is currently Overvalued.
Does Hypera SA pay dividends?
Hypera SA pays a Quarterly dividend of $0.023 which represents an annual dividend yield of 4.32%. See more information on Hypera SA dividends here
What is Hypera SA’s EPS estimate?
Hypera SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hypera SA have?
Hypera SA has 633,420,840 shares outstanding.
What happened to Hypera SA’s price movement after its last earnings report?
Hypera SA reported an EPS of $0.107 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hypera SA?
Among the largest hedge funds holding Hypera SA’s share is Fisher Asset Management LLC. It holds Hypera SA’s shares valued at N/A.
---
Hypera SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.00%
12-Months-Change
Fundamentals
Return on Equity
13.45%
Trailing 12-Months
Asset Growth
-1.00%
Trailing 12-Months
Company Description
Hypera SA
Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the major pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure.
---
HYPMY Company Deck
---
HYPMY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with notable revenue and cash flow growth, significant investments in R&D, and successful product launches. However, challenges such as a decline in specific medication categories, pressure on margins, and a competitive market environment were also highlighted. The overall sentiment is neutral given the balance between positive achievements and existing challenges.Read More>---
Technical Analysis
Dr Reddy's Laboratories
―
Takeda Pharmaceutical Company
―
Protalix
―
Axsome Therapeutics
―
---